Last edition
News about "treatment of epilepsy"
Jazz and Saniona Enter Global License Deal for Preclinical Epilepsy Candidate SAN2355
Jazz Pharmaceuticals and Saniona have entered into a global licensing agreement, giving Jazz exclusive worldwide rights to develop and commercialise SAN2355, a highly selective Kv7.2/Kv7.3 activator currently in preclinical development for epilepsy and other neurological conditions. <br />
Treatment Of Epilepsy | 21/08/2025 | By Dineshwori | 136
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members